Actelion (Actelion) Other Long-Term Liabilities : $149 Mil (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Other Long-Term Liabilities?

Actelion's other long-term liabilities for the quarter that ended in Mar. 2017 was $149 Mil.

Actelion's quarterly other long-term liabilities increased from Sep. 2016 ($123 Mil) to Dec. 2016 ($147 Mil) and increased from Dec. 2016 ($147 Mil) to Mar. 2017 ($149 Mil).

Actelion's annual other long-term liabilities increased from Dec. 2014 ($104 Mil) to Dec. 2015 ($112 Mil) and increased from Dec. 2015 ($112 Mil) to Dec. 2016 ($147 Mil).

Actelion Other Long-Term Liabilities Historical Data

The historical data trend for Actelion's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Other Long-Term Liabilities Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Other Long-Term Liabilities

Get a 7-Day Free Trial

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Actelion Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Actelion Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Actelion's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017